Filter Results:
(54)
Show Results For
- All HBS Web (54)
- Faculty Publications (22)
Show Results For
- All HBS Web (54)
- Faculty Publications (22)
- 2013
- Working Paper
Visualizing and Measuring Enterprise Architecture: An Exploratory BioPharma Case
By: Robert Lagerstrom, Carliss Baldwin, Alan MacCormack and David Dreyfus
We test a method that was designed and used previously to reveal the hidden internal architectural structure of software systems. The focus of this paper is to test if it can also uncover new facts about the components and their relationships in an enterprise... View Details
Lagerstrom, Robert, Carliss Baldwin, Alan MacCormack, and David Dreyfus. "Visualizing and Measuring Enterprise Architecture: An Exploratory BioPharma Case." Harvard Business School Working Paper, No. 13-105, June 2013.
- September 2022
- Article
Giving a Buck or Making a Buck? Donations by Pharmaceutical Manufacturers to Independent Patient Assistance Charities
By: Leemore Dafny, Christopher Ody and Teresa Rokos
The federal Anti-Kickback Statute prohibits biopharmaceutical manufacturers from directly covering Medicare enrollees’ out-of-pocket spending for the drugs they manufacture, but manufacturers may donate to independent patient assistance charities and earmark donations... View Details
Keywords: Cost Sharing; Prescription Drugs; Drug Spending; Medicare; Dual Eligibility; Cost; Health Care and Treatment; Philanthropy and Charitable Giving; Pharmaceutical Industry
Dafny, Leemore, Christopher Ody, and Teresa Rokos. "Giving a Buck or Making a Buck? Donations by Pharmaceutical Manufacturers to Independent Patient Assistance Charities." Health Affairs 41, no. 9 (September 2022).
- 27 Sep 2011
- First Look
First Look: September 27
terms expire, changes to the U.S. healthcare system are also of significance to patients and the pharmaceutical industry internationally. This article evaluates how the ACA will affect the size of the View Details
Keywords: Sean Silverthorne
- 2010
- Working Paper
Boundary Spanning in a For-profit Research Lab: An Exploration of the Interface Between Commerce and Academe
By: Christopher C. Liu and Toby E. Stuart
In innovative industries, private-sector companies increasingly are participants in open communities of science and technology. To participate in the system of exchange in such communities, firms often publicly disclose what would otherwise remain private discoveries.... View Details
Keywords: For-Profit Firms; Higher Education; Information Publishing; Innovation and Invention; Science-Based Business; Social and Collaborative Networks; Boundaries; Biotechnology Industry; Biotechnology Industry
Liu, Christopher C., and Toby E. Stuart. "Boundary Spanning in a For-profit Research Lab: An Exploration of the Interface Between Commerce and Academe." Harvard Business School Working Paper, No. 11-012, August 2010.
- August 2023
- Case
Constellation Pharmaceuticals: Corporate Development at a Novel Therapeutic Company
By: Satish Tadikonda and Brad Prosek
Constellation Pharmaceuticals was a company focused on epigenetic therapies for cancer patients. Despite a promising start and an early deal with a leading biopharma company, the company weathered twin setbacks in the end of a major research collaboration and the... View Details
Keywords: Mergers and Acquisitions; Health Care and Treatment; Organizational Change and Adaptation; Research and Development; Business Strategy; Partners and Partnerships; Goals and Objectives; Pharmaceutical Industry; United States
Tadikonda, Satish, and Brad Prosek. "Constellation Pharmaceuticals: Corporate Development at a Novel Therapeutic Company." Harvard Business School Case 824-032, August 2023.
- Web
Faculty & Advisors | MBA
Centerview in 2009, the firm has been a leading advisor to the global Biopharmaceutical industry most notable representing biotechnology companies on strategic defense. In the period from 2019 to 2021,... View Details
- Web
Sample Student Projects - Institute For Strategy And Competitiveness
Automotive Cluster (2012) Tirupur (India) Knitwear (2011) India (Maharashtra) Automotive Cluster (2010) Maharashtra Biopharmaceutical Cluster (2009) Bangalore Biotechnology (2008) Gujarat Diamonds (2008) Bollywood — Maharashtra and... View Details
- Web
Academics - Health Care
interests in organizations that provide health care (e.g., hospitals, medical groups, retail clinics) or in firms that partner with, supply, consult to, or invest in such organizations (e.g., payers, biopharmaceutical and device... View Details
- Web
Profiles - MBA
not only enhance military operations and improve the lives of service members but also transform various industries and improve society as a whole. Professional goals: My goal is to leverage my experience to bridge the gap between the... View Details
- 09 Mar 2023
- Blog Post
African American Student Union Spotlight on Joint Degrees
before and during the MBA program. Chris Egi (JD/MBA 2026) Where is your hometown? My hometown is Markham, Ontario, Canada, a suburb of the Greater Toronto Area. What was your pre-MBA industry and role? Before HBS, I was an investment... View Details
- Web
Globalization - Faculty & Research
D.C.: Carnegie Endowment for International Peace, 2024. Parexel: Scaling Up and Industry Dynamics By: Regina E. Herzlinger and Ben Creo October 2024 | Case | Faculty Research Through the lens of View Details
- 27 Mar 2012
- First Look
First Look: March 27
Corp. (B) Regina E. Herzlinger and Natalie KindredHarvard Business School Supplement 311-087 This case, the denouement to "PAREXEL International Corp. (A)," describes developments at PAREXEL and the biopharmaceutical View Details
Keywords: Carmen Nobel
- Fast Answer
R&D expenditures: Companies
- R&D Activity Data series European Commission - Economics of Industrial Research and Innovation R&D Monitor See also (in print): Research & Development Growth Trends In print: Ref T176 .R25 in... View Details
- 22 Jul 2014
- First Look
First Look: July 22
Corporate Finance Attracting Long-Term Investors Through Integrated Thinking and Reporting: A Clinical Study of a Biopharmaceutical Company By: Knauer, Andrew, and George Serafeim Abstract—Faced with a large percentage of investors that... View Details
Keywords: Sean Silverthorne
- 13 Oct 2016
- News
Adding Muscle to the Fight Against Disease
If you are one of the 17 million people who participated in the Ice Bucket Challenge a couple of summers ago, the money you helped raise to support ALS research may be at work today in a late-stage biopharmaceutical company headed by... View Details
Keywords: Deborah Blagg
- 24 Jun 2008
- First Look
First Look: June 24, 2008
Patenting on the Rate, Quality, and Direction of (Public) Research Output Authors: Pierre Azoulay, Waverly Ding, and Toby E. Stuart Periodical: Journal of Industrial Economics (forthcoming) Abstract We examine the influence of faculty... View Details
Keywords: Martha Lagace
- 28 Jul 2015
- First Look
First Look: July 28, 2015
country-level factors that limit firms' use of selective disclosure by intensifying scrutiny on them and by diffusing global norms to their headquarters countries. We test our hypotheses using a novel panel dataset of 4,750 public companies across many View Details
Keywords: Carmen Nobel
- 22 Aug 2006
- First Look
First Look: August 22, 2006
is a need for a fund like this at the time of the case. Supports discussion of specialized versus generalized venture capital funds. Purchase this case: http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=805075 John Moran and the Orthopedics View Details
Keywords: Martha Lagace
- 11 May 2010
- First Look
First Look: May 11
this case:http://cb.hbsp.harvard.edu/cb/product/610031-PDF-ENG Revitalizing Dell Jan W. RivkinHarvard Business School Case 710-442 Dell Inc., with its vaunted Direct Model, defined success in the personal computer industry for more than a... View Details
Keywords: Martha Lagace
- 18 Mar 2014
- First Look
First Look: March 18
the ratings. Our tests examine whether these forms of disclosure reflect firms' real efforts to combat corruption or are cheap talk. We find that the ratings are related to enforcement and monitoring, country and industry corruption risk,... View Details
Keywords: Sean Silverthorne